The thyrotrophin-releasing hormone (TRH)-like peptides in rat prostate are not formed by expression of the TRH gene but are suppressed by thyroid hormone.
Thyrotrophin-releasing hormone (TRH)-immunoreactive peptides were extracted from rat prostate and divided into two groups by mini-column cation exchange chromatography. The amounts of the peptides in each group were determined by radioimmunoassay with a TRH antiserum. The unretained peptides which lacked a basic group and the retained peptides which possessed a basic group were further purified by high-performance liquid chromatography. The unretained fraction was found to contain a series of TRH-immunoreactive peptides, one of which corresponded chromatographically to synthetic pGlu-Glu-Pro amide and another to pGlu-Phe-Pro amide. None of the TRH-immunoreactive peptides in either fraction exhibited the chromatographic behaviour of TRH. Additional evidence for the absence of TRH gene expression in the prostate was obtained by Northern blot analysis and by application of polymerase chain reaction amplification, which failed to reveal TRH mRNA. Furthermore the preproTRH-derived peptide, preproTRH(53-74), could not be detected by radioimmunoassay. The influence of thyroid status was investigated on the levels of the TRH-like peptides in the prostate. Adult rats were treated chronically with thyroxine (T4) or propylthiouracil (PTU) and the concentrations of the TRH-immunoreactive peptides were determined by chromatography and radioimmunoassay. Treatment with T4 caused the levels of the neutral and acidic TRH-like peptides to fall to approximately one-third of the levels in the controls. No significant difference from the controls was seen in the concentrations of the peptides in the prostates of rats rendered hypothyroid by administration of PTU. The results demonstrate that rat prostate contains TRH-immunoreactive peptides which are not derived from the TRH gene.(ABSTRACT TRUNCATED AT 250 WORDS)
Bilek
R
R
Laboratory of Peptide Chemistry, National Institute for Medical Research, Mill Hill, London.
Gkonos
P J
PJ
Tavianini
M A
MA
Smyth
D G
DG
Roos
B A
BA
D000818:Animals; D015152:Blotting, Northern; D002851:Chromatography, High Pressure Liquid; D003864:Depression, Chemical; D015870:Gene Expression; D008297:Male; D010446:Peptide Fragments / Q000032:analysis; D010455:Peptides / Q000032:analysis / Q000378:metabolism; D011441:Propylthiouracil / Q000494:pharmacology; D011467:Prostate / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D011498:Protein Precursors / Q000032:analysis; D012333:RNA, Messenger / Q000032:analysis; D011863:Radioimmunoassay; D051381:Rats; D011919:Rats, Inbred Strains; D013973:Thyrotropin-Releasing Hormone / Q000032:analysis / Q000235:genetics / Q000378:metabolism*; D013974:Thyroxine / Q000378:metabolism* / Q000494:pharmacology
D010446:Peptide Fragments; D010455:Peptides; D011498:Protein Precursors; D012333:RNA, Messenger; C058662:prepro-thyrotropin releasing hormone (53-74); D013973:Thyrotropin-Releasing Hormone; D011441:Propylthiouracil; D013974:Thyroxine